Vicore begins vital endothelial dysfunction study by John Pinching | May 3, 2023 | News | 0 The wide-ranging research aims to unlock the potential of angiotensin II type 2 receptor agonists Read More
Vicore Pharma bags MHRA nod for COVD-19 trial in record time by Selina McKee | May 1, 2020 | News | 0 ATTRACT (Angiotensin II Type Two Receptor Agonist Covid-19 Trial) is targeting hospitalised patients treated with basic respiratory care, but not mechanical ventilation Read More